CONFERENCE UPDATE: CROI 2022

Metabolic and renal side effects of monthly ISL for HIV PrEP

Get access to our exclusive articles.
Related Articles

Outcomes of NADIA trial at 96 weeks

After failure with emtricitabine (FTC) and 2 nucleoside reverse-transcriptase inhibitors (NRTIs), the recommended second-line treatment regimen for human immunodeficiency virus (HIV) from the World Health Organization (WHO) is dolutegravir (DTG) with 2 NRTIs, tenofovir disoproxil fumarate (TDF) or zidovudine (ZDV).The efficacy of this regimen has not been proven as the activity of NRTIs is thought to be limited due to drug resistance.2 Similarly, drug resistance is expected when switching TDF to ZDV.2